氟西吲哚 | 40594-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 氟西吲哚
• 中文别名: 氟辛哚
• 英文名称: N,N-dimethyl-(6,8-difluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)amine
• 英文别名: (6,8-difluoro-1,2,3,4-tetrahydro-carbazol-3-yl)-dimethyl-amine；Flucindole；3-(dimethylamino)-6,8-difluoro-1,2,3,4-tetrahydrocarbazole；6,8-difluoro-N,N-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-3-amine
• CAS: 40594-09-0
• 化学式: C₁₄H₁₆F₂N₂
• 分子量: 250.291
• InChiKey: FXNCRITWFOVSEP-UHFFFAOYSA-N

物化性质

• 熔点：
  181-183 °C(Solv: acetic acid (64-19-7))
• 沸点：
  365.1±42.0 °C(Predicted)
• 密度：
  1.25

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氟西吲哚 、 苯磺酰氯 在 potassium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 3.0h， 生成 N,N-dimethyl-(9-benzenesulfonyl-6,8-difluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)amine
  参考文献：
  名称：

  N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists

  摘要：

  The design, synthesis and SAR of novel tetrahydrocarbazole derivatives having 5-HT6 receptor antagonist activity is presented. The racemic compound 15e was found to possess desirable pharmacokinetic properties, adequate brain penetration and activity in animal models of cognition. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.002
• 作为产物：
  描述：

  4-(二甲基氨基)环己酮盐酸盐 、 (2,4-二氟苯基)肼盐酸盐(1:1) 以 乙醇 、 水 为溶剂， 生成 氟西吲哚
  参考文献：
  名称：

  3-Hydroxy carbazole derivatives

  摘要：

  3-(取代氨基)-1,2,3,4-四氢咔唑烯通过将适当的4-取代氨基环己酮与苯基肼反应制备，通过将3-(磺酸酯氧基)-1,2,3,4-四氢咔唑烯与适当的取代胺反应制备，或者通过还原适当的3-(酰胺基)-1,2,3,4-四氢咔唑烯来制备。本发明的3-(取代氨基)-1,2,3,4-四氢咔唑烯具有镇痛和精神活性。此外，其中一些化合物还具有抗组胺活性。

  公开号：

  US04062864A1

文献信息

• Co-administration of dopamine-receptor binding compounds
  申请人：Fernandes B. Prabhavathi

  公开号：US20070155720A1

  公开（公告）日：2007-07-05

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗患有神经、精神和精神障碍的患者的方法，包括向患者施用部分和/或全多巴胺D1受体激动剂的有效量，并向患者施用多巴胺D2受体拮抗剂的有效量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以以相同或不同的组合或组合物形式向患者施用。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DREADD ACTUATORS<br/>[FR] ACTIONNEURS DREADD
  申请人：US HEALTH

  公开号：WO2019157083A1

  公开（公告）日：2019-08-15

  Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.

  公开了一种化合物的化学式(I)，其中R1、R2和R3如本文所述。还提供了包含化合物的药物组合物的制剂(I)和使用化合物的方法(I)，包括治疗疾病或紊乱的方法以及在受试者中实现G蛋白偶联受体(GPCR)介导的反应的方法。
• 3-Amido-1,2,3,4-tetrahydrocarbazoles
  申请人：Sterling Drug Inc.

  公开号：US03959309A1

  公开（公告）日：1976-05-25

  3-(Substituted-amino)-1,2,3,4-tetrahydrocarbazoles are prepared by reacting appropriate 4-substituted-aminocyclohexanones with a phenylhydrazine, by reacting a 3-(sulfonyloxy)-1,2,3,4-tetrahydrocarbazole with an appropriate substituted amine, or by reduction of an appropriate 3-(acylamino)-1,2,3,4-tetrahydrocarbazole. The 3-(substituted-amino)-1,2,3,4-tetrahydrocarbazoles of this invention have analgetic and psychotropic activities. Moreover, certain of these compounds also have antihistaminic activity.

  通过将适当的4-取代氨基环己酮与苯基肼反应，通过将3-(磺酰氧基)-1,2,3,4-四氢咔唑与适当的取代胺反应，或者通过还原适当的3-(酰胺基)-1,2,3,4-四氢咔唑，可以制备3-(取代氨基)-1,2,3,4-四氢咔唑。本发明的这些3-(取代氨基)-1,2,3,4-四氢咔唑具有镇痛和精神活性。此外，这些化合物中的某些化合物还具有抗组胺活性。